Chronic coronary syndrome
Conditions
Brief summary
Level of platelet reactivity, measured as Platelet Reaction Unit, as measured by the VerifyNow system
Detailed description
To determine if the CYP2C19 genotype has additional effect on the platelet reactivity in the different treatment groups., To assess the difference between PRU values in the high bodyweight/BMI group during clopidogrel treatment and prasugrel treatment., To assess possible confounders for HTPR., Mortality (and cause of mortality), Myocardial infarction, Stent thrombosis, Revascularization, Stroke, Bleedings, To correlate the measured body fat percentages with PRU values.
Interventions
Sponsors
Sint Antonius Ziekenhuis Stichting
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of platelet reactivity, measured as Platelet Reaction Unit, as measured by the VerifyNow system | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine if the CYP2C19 genotype has additional effect on the platelet reactivity in the different treatment groups., To assess the difference between PRU values in the high bodyweight/BMI group during clopidogrel treatment and prasugrel treatment., To assess possible confounders for HTPR., Mortality (and cause of mortality), Myocardial infarction, Stent thrombosis, Revascularization, Stroke, Bleedings, To correlate the measured body fat percentages with PRU values. | — |
Countries
Netherlands
Outcome results
None listed